The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Classic: Streptomycin, a Substance Exhibiting Antibiotic Activity against Gram-Positive and Gram-Negative Bacteria
Abstract
Selman Waksman (Figs 1, 2) came to the United States from Imperial Russia in 1910 when he was in his early 20s. He entered Rutgers University in New Jersey a year later and became a soil microbiologist at the Agriculture College there. He observed that certain fungi in soil suppressed the growth of mycobacterium tuberculosis and eventually he and the workers in his laboratory (including his co-authors on this classic article, Albert Schatz and Elizabeth Bugie) isolated one that proved extremely effective and minimally toxic-streptomycin.Fig 1.: Selman Waksman (right) is shown with Albert Schatz. The two were co-discoverers of streptomycin.Fig 2.: Selman Waksman (left) is shown with Sir Albert Fleming, who discovered penicillin.Selman Waksman claimed (and received the credit for) the discovery of streptomycin in the mid 1940s). With the credit came fame and fortune, which included a Nobel Prize and medals and accolades from numerous nations, prestigious societies, and universities. It also brought a great deal of money. Elizabeth Bugie and Albert Schatz, Waksman’s putative collaborators, objected to Waksman’s one-sided winnings and eventually filed a lawsuit against him for what they considered to be their fair share. Waksman argued that he, as the director of the laboratory at Rutgers University, had spent 30 years perfecting the techniques that made the discovery possible. Schatz, as a PhD worker in the laboratory, had done the work but only under Waksman’s direction and using Waksman’s methods. Elizabeth Bugie, another worker in the laboratory, had only been asked to corroborate Schatz’s work, and she eventually withdrew from the civil action. In the end Waksman got 10% of the money derived from the sale of the streptomycin patent, Schatz got 3%, and all others employed in the laboratory (and they were many) split 7%. Rutgers University got 80% and with it built the Waksman Institute of Microbiology, which became a major research institution in that field. The accompanying paper by Bosworth et al was published previously in CORR as a Classic Article. It documents the effectiveness of streptomycin in treating the draining sinuses of tuberculosis. In it Bosworth et al note that the use of streptomycin resulted in “dramatic healing of sinuses and a marked improvement in general physical condition” in about 80% of the 95 patients in their review. The patients who did not have such a good outcome had sequestra, thick walled abscesses, or uncontrolled dead spaces, all of which were amenable to surgical intervention because of the effect of streptomycin. With the exception of streptothricin,1 most of the antibiotic substances known at the present time, including penicillin and other mold products as well as gramicidin and actinomycin, act largely upon gram-positive bacteria. The activity of these substances upon gram-negative organisms is highly selective as in the case of penicillin, which affects the Neisseria group and has little activity upon Escherichia coli and other gram-negative bacteria,2 or else much larger quantities are required to bring about the inhibition of these bacteria, as in the case of actinomycin.3 Among the antibiotic agents that act selectively alike against both gram-positive and gram-negative bacteria, streptothricin occupies a prominent place; since this substance is water-soluble and possesses limited toxicity to animals, it is of particular interest from a chemotherapeutic point of view. Unfortunately, streptothricin has very little activity against a number of bacteria found among both the gram-negative (Pseudomonas fluorescens, Ps. aeruginosa) and the gram-positive (Bacillus mycoides and B. cereus) groups. In a search for antagonistic organisms that are active against gram-negative bacteria, and from which antibiotic substances could be isolated, the actinomycetes were found4 to offer extensive potentialities. Although most of the antibacterial agents produced by these organisms are also active against gram-positive bacteria, certain few of them exert a marked selective activity against many of the gram-negative types of bacteria. Actinomyces lavendulæ, which produces streptothricin is such an organism. After detailed examination of a large number of cultures, either isolated at random from different natural and enriched soils and composts, or selected from the culture collection, another oganism was found that produces an antibiotic substance which apparently combines many of the desirable antibacterial properties. This organism is similar, in most of its cultural characteristics as well as in its morphology, to A. griseus isolated from the soil some 28 years ago.5 The active substance is in many respects similar to streptothricin, although it differs from it in its greater activity against various gram-negative bacteria, notably the Ps. aeruginosa group, as well as against those aerobic spore-forming bacteria, such as B. mycoides, which are resistant to streptothricin. Because of
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Waksman, S. A., & Woodruff, H. B. (1941) · Journal of Bacteriology · doi:10.1128/jb.42.2.231-249.1941 · Cited by 134
Self-citation
Research works printed but not linked: 2
- Waksman, 1943, Bact, 46, 299, 10.1128/JB.46.3.299-310.1943 · doi:10.1128/jb.46.3.299-310.1943
- Waksman, 1942, Bact, 44, 571, 10.1128/JB.44.5.571-588.1942 · doi:10.1128/jb.44.5.571-588.1942
Cited by
A new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
Rhizosphere microbiome assemblage is affected by plant development
Chaparro, J. M., Badri, D. V., & Vivanco, J. M. (2014) · The ISME Journal · doi:10.1038/ismej.2013.196 · Cited by 1,578
Platforms for antibiotic discovery
Lewis, K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3975 · Cited by 1,445
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
A Review of the Microbial Production of Bioactive Natural Products and Biologics
Pham, J. V., Yilma, M. A., Feliz, A., Majid, M. T., Maffetone, N., Walker, J. R., Kim, E., Cho, H. J., Reynolds, J. M., Song, M. C., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01404 · Cited by 565
Metadata
- Authors
- Schatz, A., Bugie, E., Waksman, S. A., Hanssen, A. D., Patel, R., & Osmon, D. R.
- Venue
- Clinical Orthopaedics and Related Research
- Published
- 2005-08
- Volume
- &NA;
- Issue
- 437
- Pages
- 3-6
- ISSN
- 0009-921X (ISSN-L)
- OpenAlex
- W194343785
- Cited by
- 305
- References
- 1
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Classic: Streptomycin, a Substance Exhibiting Antibiotic Activity against Gram-Positive and Gram-Negative Bacteria. https://app.cochat.ai/papers/10.1097/01.blo.0000175887.98112.fe
- The paper
- Schatz, A., Bugie, E., Waksman, S. A., Hanssen, A. D., Patel, R., & Osmon, D. R. (2005). The Classic: Streptomycin, a Substance Exhibiting Antibiotic Activity against Gram-Positive and Gram-Negative Bacteria. Clinical Orthopaedics and Related Research. https://doi.org/10.1097/01.blo.0000175887.98112.fe
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.